Stevanato Group extends licensing agreement with Haselmeier for pen injector tech

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology.

Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorder, arthritis and more.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0